{"url":"https://lda.senate.gov/api/v1/filings/51f786eb-05d6-4702-8cfd-e65daaa02bb0/","filing_uuid":"51f786eb-05d6-4702-8cfd-e65daaa02bb0","filing_type":"3A","filing_type_display":"3rd Quarter - Amendment","filing_year":2024,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/51f786eb-05d6-4702-8cfd-e65daaa02bb0/print/","filing_document_content_type":"text/html","income":null,"expenses":"230000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Julian Malasi","dt_posted":"2025-01-21T13:57:09-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"400 Crossing Boulevard","registrant_address_2":"3rd Floor","registrant_different_address":false,"registrant_city":"Bridgewater","registrant_state":"NJ","registrant_zip":"08807","registrant":{"id":401108064,"url":"https://lda.senate.gov/api/v1/registrants/401108064/","house_registrant_id":56347,"name":"AMNEAL PHARMACEUTICALS","description":null,"address_1":"400 Crossing Boulevard","address_2":"3rd Floor","address_3":null,"address_4":null,"city":"Bridgewater","state":"NJ","state_display":"New Jersey","zip":"08807","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JULIAN MALASI","contact_telephone":"+1 843-330-9995","dt_updated":"2026-07-23T19:46:49.584545-04:00"},"client":{"id":58532,"url":"https://lda.senate.gov/api/v1/clients/58532/","client_id":58532,"name":"AMNEAL PHARMACEUTICALS","general_description":"Pharmaceutical company","client_government_entity":null,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Addressing drug shortages and enhancing domestic production of critical medicines Issues related to biosimilars Promoting long-term sustainability of access for patients to generic and biosimilar medicines H.R.1503/S.2916: Prescription Information Modernization Act of 2023 H.R.2880: Protecting Patients Against PBM Abuses Act H.R.5429/S.2780: Medication Affordability and Patent Integrity Act 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024 Lower Costs, More Transparency Act (H.R. 5378) H.R.6109: Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act S.2305: Biosimilar Red Tape Elimination Act Appropriations pertaining to American Made preference for generic products Issues related to Medicaid Generics Penalty Issues related to the IRA Issues related to drug supply chain Senate Finance Committee drug shortage legislation Proposals related to drug shortages","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145310,"prefix":null,"prefix_display":null,"first_name":"JULIAN","nickname":null,"middle_name":null,"last_name":"MALASI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}